NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T
CRISPR Therapeutics (NasdaqGM:CRSP) has moved its allogeneic CAR T candidate CTX112 into Phase 1 clinical trials.
The program targets lymphoma and certain autoimmune diseases with an off the shelf cell therapy approach.
The company is positioning CTX112 within the broader CAR T market, which currently relies heavily on individualized patient specific treatments.
For investors following CRISPR Therapeutics, CTX112 marks a meaningful extension of the company’s focus beyond its earlier gene...